06. January 2018
Outsourcing in the bio/pharmaceutical industry had a productive 2017. A flurry of acquisitions, an expansion of biotechnology needs, and a growth in new facilities and services offered were seen. The following are some of the highlights.
18. October 2017
How can CDMOs play a better, more strategic role in the greater pharma supply chain and better serve their customers? Instead of relying on organic market growth alone to propel revenue and profitability, what can CDMOs do differently? Could Big Pharma and CDMOs consider joint ownership or build and operate new business models? And, as globalisation affects the worldwide CDMO market, what are threats and opportunities, and how do CDMOs develop a sustainable business model in this landscape?...
11. May 2017
Established in 2008 and now celebrating our 10th consecutive year, the scope of BOS cmc 2017 will cover development stage CMC outsourcing for both small molecules and biologics (including novel therapeutic entities such as cell therapies and gene therapies). Our programme is divided into small molecule and biologics tracks and includes the following modules: Outsourcing Business Process: Building Effective Outsourcing Partnerships: Early Development Outsourcing: Late Stage Outsourcing: Drug Deli